Pharmaceuticals

Global Gastric Cancer Drugs Industry Trends: Where the Market Is Headed by 2029

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Was The Gastric Cancer Drugs Market Worth In 2025, And What Is Its Anticipated Value By 2029?

The gastric cancer drugs market size has experienced significant expansion over recent years. This market is projected to expand from $4.41 billion in 2024 to $4.9 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 11.2%. Factors contributing to its historical growth include a rise in pharmaceutical R&D expenditure, higher healthcare spending, robust economic growth in emerging markets, and a swiftly increasing elderly population.

The gastric cancer drugs market size is projected to experience swift expansion over the coming years, reaching $7.35 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 10.7%. This anticipated growth during the forecast period can be attributed to several factors, including an uptick in gastric cancer incidence rates, a robust pipeline of new drugs, an increase in acquisitions and partnerships, rising healthcare expenditure, a growing geriatric population, and updated FDA regulations designed to facilitate biologics drug development. Key trends expected in this period encompass strategic collaborations and agreements aimed at expanding product portfolios, fostering partnerships with other companies or governmental entities, enhancing the volume of pipeline studies dedicated to developing gastric cancer drugs, channeling investments into AI solutions to diminish research and development costs, advancing next-generation biologics, and incorporating CRISPR-Cas9 technology in the creation of new medications.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2603&type=smp

What Are The Key Drivers Of Growth In The Gastric Cancer Drugs Market?

The growing prevalence of obesity alongside an expanding smoking population has led to a rise in individuals diagnosed with gastric cancer. The consumption of tobacco and adherence to an unhealthy diet are factors that escalate the risk of stomach cancer. For example, in May 2023, according to the Government Digital Service, a UK-based government body, it was projected that 25.9% of individuals (18 years and older) in England were obese in 2022–2022, a figure which has increased by 25.2%. Such an increase in gastric cancer cases is anticipated to drive the growth of the gastric cancer drugs market.

What Are The Key Segments In The Gastric Cancer Drugs Market?

The gastric cancer drugs market covered in this report is segmented –

1) By Type: Imatinib, Trastuzumab, Other Types

2) By Route of Administration: Oral, Parenteral

3) By End User: Hospitals, Clinics, Cancer Speciality Centers

Subsegments:

1) By Imatinib: Oral Formulations, Injectable Formulations, Combination Therapies

2) By Trastuzumab: Monotherapy, Combination Therapy With Chemotherapy, Biosimilars Of Trastuzumab

3) By Other Types: Chemotherapy Agents, Targeted Therapy Agents, Immunotherapy Agents, Supportive Care Medications

What Are The Major Trends Driving The Growth Of The Gastric Cancer Drugs Market?

Companies operating within the gastric cancer drugs market are innovating advanced products, such as anti-PD-1 therapies, to enhance treatment efficacy and improve patient outcomes. Anti-PD-1 therapy functions as a type of immunotherapy that targets the programmed cell death protein 1 (PD-1) receptor on immune cells. For instance, in November 2023, Merck & Co., Inc., a US-based pharmaceutical company, received approval from the Food and Drug Administration (FDA), a US-based federal agency for protecting the public health, for KEYTRUDA (pembrolizumab). KEYTRUDA (pembrolizumab) is an anti-PD-1 therapy utilized for treating gastric cancer. This medication is indicated for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. Its application is specifically for use in combination with trastuzumab, as well as fluoropyrimidine- and platinum-containing chemotherapy. This indication has been granted accelerated approval based on the tumor response rate and the duration of that response.

Who Are The Major Companies Operating In The Gastric Cancer Drugs Market?

Major companies operating in the gastric cancer drugs market include F. Hoffmann-La Roche, Eli Lilly and Company, Otsuka Pharmaceutical, Jiangsu HengRui Medicine, Biocon, Sanofi, PV Pharma Healthcare (India), Roche India, Novartis Oncology, Arlak Biotech (India), Healthkind labs Pvt. Ltd., SwisscheM Healthcare Pvt.Ltd, Apikos Pharma, Kolaz biotech., CStone Pharma (China), CARsgen Therapeutics (China), JW Therapeutics (China), BeiGene(China), Takeda Pharmaceuticals (Japan), Astellas Pharma Inc (Japan), Daiichi Pharmaceutical and Sankyo (Japan), AQVIDA GmbH, AstraZeneca plc, GlaxoSmithKline plc, Veropharm, Biocad, Bristol-Myers Squibb, Celon Pharma, Celltrion Inc., Imugene Limited, Merck & Co. Inc., Pfizer Inc., Sandoz AG (A Novartis Division), Eurofarma Laboratórios S.A., TUTEUR ArgentinaPierre Fabre Group, Celnova Pharma, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO), Gulf Pharmaceutical Industries (Julphar), Abbott Laboratories, Mylan Laboratories, Gilead Sciences, BMS, Ascedis Health

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

Which Region Is Expected To Witness The Fastest Growth In The Gastric Cancer Drugs Market?

North America was the largest region in the gastric cancer drugs market in 2024. Middle East is expected to be the largest growing region in the global gastric cancer drugs market share during the forecast period. The regions covered in the gastric cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Gastric Cancer Drugs Market Report:

https://www.thebusinessresearchcompany.com/customise?id=2603&type=smp

Browse Through More Reports Similar to the Global Gastric Cancer Drugs Market 2025, By The Business Research Company

Diuretics Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/diuretics-drugs-global-market-report

Genito Urinary Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/genito-urinary-drugs-global-market-report

Dermatology Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795